SSC
VRTX icon

Syverson Strege & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Syverson Strege & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-635
Closed -$283K – 174
2025
Q2 		$283K Buy
+635
New +$293K 0.07% 122
2023
Q2 		– Sell
-26
Closed -$8.19K – 607
2023
Q1 		$8.19K Buy
+26
New +$7.8K ﹤0.01% 272

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Syverson Strege & Co's VRTX Position: Q3 2025 in Review

Syverson Strege & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 635 shares — an estimated $283K sold.

Syverson Strege & Co first reported a position in VRTX in Q1 2023 and held it in 2 quarters. The position peaked at $283K in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Syverson Strege & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Syverson Strege & Co sold 635 Vertex Pharmaceuticals shares in Q3 2025, an estimated $283K.
  • Syverson Strege & Co first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Syverson Strege & Co's Vertex Pharmaceuticals position peaked at $283K in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Syverson Strege & Co's 13F filing for Q3 2025, filed 1 Dec 2025.